Research programme: diabetes/obesity therapies - ChemGenex Pharmaceuticals/Merck-Sante

Drug Profile

Research programme: diabetes/obesity therapies - ChemGenex Pharmaceuticals/Merck-Sante

Alternative Names: CXS-102 SelS; CXS-121 SGIP1; CXS-203 PSARL

Latest Information Update: 30 Oct 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemGenex Pharmaceuticals; Merck Sante
  • Class
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2008 Discontinued - Preclinical for Obesity in Australia (unspecified route)
  • 30 Oct 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in Australia (unspecified route)
  • 20 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top